The lysosomotropic drug derived from betulinic acid, B10, has been shown to enhance the effects of the BCL-2 inhibitor ABT-263, increasing lysosomal permeabilization and activating LDCD in different ALL models [175]. Here, BCL2 is linked to acute lymphoblastic leukemia.